Tazemetostat Clinical Trials
11 recruitingDrug
Phase 18Phase 25Phase 31
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.100 enrolled2 locationsNCT07407283
Recruiting
Phase 1
Tazemetostat and Palbociclib With CPX-351for R/R AML
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Thomas Jefferson University24 enrolled1 locationNCT05627232
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 1
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Advanced Malignant Solid TumorHepatic Impairment
Epizyme, Inc.24 enrolled18 locationsNCT04241835
Recruiting
Phase 2
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
B-cell Non Hodgkin Lymphoma
Northwestern University32 enrolled2 locationsNCT06242834
Recruiting
Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701
Recruiting
Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Grade 3b Follicular Lymphoma
SWOG Cancer Research Network227 enrolled104 locationsNCT05890352
Recruiting
Phase 1Phase 2
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Susan Chi, MD49 enrolled3 locationsNCT05407441
Recruiting
Phase 1
Study of Tazemetostat in Lymphoid Malignancies
T-cell Lymphoma
University of Alabama at Birmingham30 enrolled1 locationNCT05983965
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb260 enrolled17 locationsNCT05372354
Recruiting
Phase 1
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaLymphoma, Non-HodgkinFollicular Lymphoma
Weill Medical College of Cornell University38 enrolled1 locationNCT05618366